Will M&A boost biotech?
This article was originally published in Scrip
Executive Summary
The past few weeks have been a busy one on the M&A front. The marquee event is clearly Sanofi-Aventis's now very hostile bid for Genzyme, but the acquisitions of Crucell by Johnson & Johnson and ZymoGenetics by Bristol-Myers Squibb may have consequences for the biotech industry that go beyond big pharma companies bolstering their own portfolios.